Business
Dyadic to Report First Quarter 2020 Financial Results on Thursday, May 14, 2020
JUPITER, FL / ACCESSWIRE / April 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving
About this update from Dyadic International, Inc.
[{"type":"text","content":"JUPITER, FL / ACCESSWIRE / April 30, 2020 / Dyadic International, Inc. (\"Dyadic\") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2020 after the market close on Thursday, May 14, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.Conference Call InformationDate: Thursday, May 14, 2020Time: 5:00 p.m. Eastern TimeDial-in numbers: (877) 407-8033 (U.S. or Canada) or +(201) 689-8033 (International)No pass code is neededWebcast Link: https://www.webcaster4.com/Webcast/Page/2031/34441An archive of the webcast will be available approximately three hours after completion of the live event and will be accessible on the \"Investors\" section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the Webcast link above. A dial-in replay of the call will also be available to those interested. To access the replay which will expire May 28, 2020, dial 1 (877) 481-4010 (U.S. or Canada) or 1 (919) 882-2331 (International) and enter replay pass code: 34441.About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic protein...